WAM
INO icon

Wolverine Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Wolverine Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,500
Closed -$53.1K – 1796
2025
Q4 		$53.1K Buy
+30,500
New +$67.2K ﹤0.01% 1271
2025
Q1 		– Sell
-97,400
Closed -$178K – 1670
2024
Q4 		$178K Buy
+97,400
New +$431K ﹤0.01% 1046
2020
Q4 		– Sell
-350
Closed -$46.6K – 1758
2020
Q3 		$48K Buy
+350
New +$73K ﹤0.01% 1271

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wolverine Asset Management's INO Position: Q1 2026 in Review

Wolverine Asset Management sold out of Inovio Pharmaceuticals (INO) in Q1 2026, closing a stake of 30,500 shares — an estimated $53.1K sold.

Wolverine Asset Management first reported a position in INO in Q3 2020 and held it in 3 quarters. The position peaked at $178K in Q4 2024. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Wolverine Asset Management reported no remaining Inovio Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 30,500 Inovio Pharmaceuticals shares in Q1 2026, an estimated $53.1K.
  • Wolverine Asset Management first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Wolverine Asset Management's Inovio Pharmaceuticals position peaked at $178K in Q4 2024.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.